Internal Medicine最新文献_第8页

An Autopsy Case of Varicella-zoster Virus Uveitis Progressing to Vasculopathy with Multiple Cerebral Infarctions. 水痘带状疱疹病毒葡萄膜炎进展为血管病变伴多发性脑梗死的尸检一例。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-29 DOI: 10.2169/internalmedicine.4511-24

Hiroaki Ando, Yuichi Kawagashira, Jun-Ichi Niwa, Akio Akagi, Manabu Doyu

引用次数: 0

Plasma Cell-rich Nephritis with a Systemic Polyclonal Lymphoproliferative Disorder, Mimicking Idiopathic Multicentric Castleman Disease, Systemic Lupus Erythematosus, and IgG4-related Disease. 富浆细胞肾炎伴全身性多克隆淋巴增生性疾病，模拟特发性多中心Castleman病、系统性红斑狼疮和igg4相关疾病

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-22 DOI: 10.2169/internalmedicine.4906-24

Yu Hebisawa, Akihito Ohta, Ryutaro Sekimoto, Natsuko Sakurai, Keigo Setoguchi

引用次数: 0

Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and Its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study. Lusutrombopag在临床应用中的有效性及其与模拟软件预测血小板计数的相关性：一项多中心研究。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-15 DOI: 10.2169/internalmedicine.4822-24

Takushi Manabe, Chikara Ogawa, Takashi Tamada, Naoki Yoshioka, Takehiro Akahane, Hideki Fujii, Hirotaka Arai, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Asahiro Morishita, Hideki Kobara, Shinichiro Nakamura, Hironori Ochi, Shintaro Takaki, Nami Mori, Keiji Tsuji, Masayuki Kurosaki, Namiki Izumi

{"title":"Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and Its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study.","authors":"Takushi Manabe, Chikara Ogawa, Takashi Tamada, Naoki Yoshioka, Takehiro Akahane, Hideki Fujii, Hirotaka Arai, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Asahiro Morishita, Hideki Kobara, Shinichiro Nakamura, Hironori Ochi, Shintaro Takaki, Nami Mori, Keiji Tsuji, Masayuki Kurosaki, Namiki Izumi","doi":"10.2169/internalmedicine.4822-24","DOIUrl":"10.2169/internalmedicine.4822-24","url":null,"abstract":"Objective Lusutrombopag is recommended for severe thrombocytopenia (<5.0×104/μL) in patients with chronic liver disease who are scheduled to undergo invasive procedures. However, reports on the efficacy of repeated lusutrombopag dosing are scarce. It is also not known whether lusutrombopag causes the platelet count to exceed 5.0×104/μL. We evaluated the efficacy of repeated lusutrombopag dosing and the efficacy of the platelet prediction simulation software program. Methods We evaluated the number of platelet elevations according to the number of lusutrombopag administrations. We also evaluated the correlation between the highest software-predicted platelet count and the platelet count measured in actual clinical practice. Patients This retrospective study included 236 patients treated with lusutrombopag at 11 medical institutions in Japan. Results The platelet count increased with the number of lusutrombopag administrations (1, 2, 3, 4, >4) in all groups, and no significant difference was found among the groups (p=0.169). In all groups, the platelet counts reached their highest levels at 8-14 days after treatment with lusutrombopag (p=0.243). There was a correlation between the highest software-predicted platelet count and the platelet count measured in actual clinical practice in all dose frequency groups; however, the correlation was the strongest in the one-dose group (r=0.74, p<0.0001). Conclusion Frequent lusutrombopag administration is therefore both effective and safe, and a platelet prediction simulation software program is thus considered to be useful in practice.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"2692-2698"},"PeriodicalIF":1.1,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12508629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rapidly Enlarged Azygos Vein Aneurysm with Thrombosis. 迅速增大的奇静脉动脉瘤伴血栓形成。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-08 DOI: 10.2169/internalmedicine.4986-24

Hiroaki Fujisawa, Kenji Umeki, Kosaku Komiya

引用次数: 0

Inherited Prion Disease with a 5-octapeptide Repeat Insertion in the PRNP Gene Presenting with Familial Juvenile Dementia. PRNP基因中5-八肽重复插入的遗传性朊病毒疾病表现为家族性青少年痴呆：一例报告。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-08 DOI: 10.2169/internalmedicine.5143-24

Masafumi Nishikawa, Akitoshi Takeda, Naotaka Miyazawa, Norikazu Hara, Kazunari Ishii, Takeshi Ikeuchi, Yoshiaki Itoh

引用次数: 0

Stationary Oxygen Concentrator with Built-in Respiratory Rate Monitor: Clinical Validation of Its Efficacy in Patients with Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease. 固定式氧浓缩器内置呼吸速率监测仪：对间质性肺疾病和慢性阻塞性肺疾病疗效的临床验证。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-08 DOI: 10.2169/internalmedicine.5012-24

Satoshi Hamada, Tomohiro Handa, Kimihiko Murase, Naoya Tanabe, Yoshinari Nakatsuka, Kohei Ikezoe, Hironobu Sunadome, Susumu Sato, Atsuyasu Sato, Toyohiro Hirai

{"title":"Stationary Oxygen Concentrator with Built-in Respiratory Rate Monitor: Clinical Validation of Its Efficacy in Patients with Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease.","authors":"Satoshi Hamada, Tomohiro Handa, Kimihiko Murase, Naoya Tanabe, Yoshinari Nakatsuka, Kohei Ikezoe, Hironobu Sunadome, Susumu Sato, Atsuyasu Sato, Toyohiro Hirai","doi":"10.2169/internalmedicine.5012-24","DOIUrl":"10.2169/internalmedicine.5012-24","url":null,"abstract":"Objective The respiratory rate (RR) can be monitored continuously using a HiSanso®i, a stationary oxygen concentrator with a built-in respiratory sensor. To examine the efficacy of this device, we compared its performance with that of polysomnography in inpatient settings and the home sleep apnea test (HSAT) in residential settings for patients with interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). Methods The oxygen flow rate was set at 1, 3, and 5 L/min in inpatient settings and 1-3 L/min (conditions similar to the home surroundings) in residential settings. Intraclass correlation coefficients (ICCs) (2,1) were calculated to determine the agreement between the RR measured with the HiSanso®i and that measured with polysomnography or the HSAT. The minimum acceptable reliability level is 0.7. Results In total, 14 (10 with ILD and 4 with COPD) and 5 (all with ILD) patients were assessed in inpatient and residential settings, respectively. In inpatient settings, the detection rate of patients' respiration measured with the HiSanso®i was 77.0% and 73.3% in patients with ILD and COPD, respectively. At oxygen flow rates of 1, 3, and 5 L/min, the ICCs (2,1) were 0.91, 0.85, and 0.91, respectively, for patients with ILD and 0.96, 0.90, and 0.74, respectively, for patients with COPD. In residential settings, the detection rate of patients' respiration measured with the HiSanso®i was 86.6%, and the ICC (2,1) was 0.97. Conclusion The HiSanso®i accurately monitored the RR without any additional devices, independent of oxygen flow rates or disease status.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"2708-2715"},"PeriodicalIF":1.1,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12508631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma. 高风险弥漫性大b细胞淋巴瘤高剂量甲氨蝶呤预防后延迟甲氨蝶呤消除。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-15 DOI: 10.2169/internalmedicine.4999-24

Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Kenji Matsumoto, Chizuko Hashimoto, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Hideaki Nakajima

{"title":"Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma.","authors":"Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Kenji Matsumoto, Chizuko Hashimoto, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Hideaki Nakajima","doi":"10.2169/internalmedicine.4999-24","DOIUrl":"10.2169/internalmedicine.4999-24","url":null,"abstract":"Objective High-dose methotrexate (HD-MTX) is widely used as central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL) who are at a high risk of CNS relapse. Ensuring safe prophylactic administration with minimal adverse events is a key concern; however, few studies have detailed the safety profile of HD-MTX prophylaxis in patients with high-risk DLBCL. We analyzed the adverse events associated with HD-MTX in this population, focusing on delayed MTX elimination. Methods This multicenter retrospective study included 98 patients with DLBCL at high risk of CNS relapse who received HD-MTX as part of frontline therapy between 2014 and 2020. CNS prophylaxis involved 2 cycles of HD-MTX (3.0 g/m2) at 2-week intervals. Results The median age at the diagnosis was 63 (34-84) years old, and 34 patients received a reduced methotrexate (MTX) dose. The overall incidence of delayed MTX elimination was 18.4%. No cases of delayed MTX elimination were observed in the group that received a 3-h MTX infusion (n=50). Toxicities were more frequent in patients with delayed MTX elimination than in those without (77.8% vs. 26.2%, p≤0.05), including higher incidences of grade ≥3 adverse events and grade ≤2 renal dysfunction. Conclusion Delayed MTX elimination is associated with increased complications. Shorter MTX infusion rates, particularly at 3 h, may reduce the risk of delayed MTX elimination.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"2716-2722"},"PeriodicalIF":1.1,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12508606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thyrotoxicosis and Excess Iodine Due to Habitual Use of Polyvinylpyrrolidone Iodine While Gargling in an Iodine-sufficient Area. 足碘地区含碘时习惯性使用聚乙烯吡咯烷酮碘致甲状腺毒症和碘过量1例。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-15 Epub Date: 2025-03-22 DOI: 10.2169/internalmedicine.4868-24

Kanako Sato, Hiroaki Asai, Saori Yoshioka, Keisuke Murakawa, Hiroyuki Sho, Ryoko Inui, Motohiro Kosugi, Yoji Hazama, Tetsuyuki Yasuda

引用次数: 0

Randomized Prospective Controlled Open-labeled Trial of Cyclosporine with/without Low-dose Oral Corticosteroids in Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome. 环孢素联合/不联合低剂量口服皮质类固醇治疗成人肾病综合征特发性膜性肾病的随机前瞻性对照开放标记试验

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-01 Epub Date: 2025-02-22 DOI: 10.2169/internalmedicine.4803-24

Joichi Usui, Kouichi Hirayama, Masaki Kobayashi, Satoshi Suzuki, Itaru Ebihara, Kenta Nishiki, Kaori Mase, Aki Hirayama, Chie Saito, Michihiro Goto, Akio Koyama, Kunihiro Yamagata

{"title":"Randomized Prospective Controlled Open-labeled Trial of Cyclosporine with/without Low-dose Oral Corticosteroids in Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome.","authors":"Joichi Usui, Kouichi Hirayama, Masaki Kobayashi, Satoshi Suzuki, Itaru Ebihara, Kenta Nishiki, Kaori Mase, Aki Hirayama, Chie Saito, Michihiro Goto, Akio Koyama, Kunihiro Yamagata","doi":"10.2169/internalmedicine.4803-24","DOIUrl":"10.2169/internalmedicine.4803-24","url":null,"abstract":"Objective We conducted a prospective, randomized controlled, open-label study to investigate the efficacy of a combination of cyclosporine and low-dose prednisolone in patients with idiopathic membranous nephropathy (IMN). Methods We recruited biopsy-proven IMN patients with nephrotic syndrome who had never been treated with immunosuppressants. The patients were randomized into 2 groups treated after randomization with cyclosporine (3 mg/kg/day) alone or with an oral low-dose corticosteroid (prednisolone 15 mg/day) for 24 months. Results We recruited 30 patients with IMN and nephrotic-range proteinuria, 28 of whom were included in this study. Fourteen patients were randomized for treatment with only cyclosporine (Group A), and 14 were randomized for treatment with cyclosporine plus low-dose corticosteroids (Group B). Cyclosporine monotherapy induced remission in 12 of the 14 patients in Group A, including partial remission in 7 patients (50.0%) and complete remission in 5 patients (36.7%). In Group B, 12 of 14 patients achieved proteinuria remission, including 11 (78.6%) with complete remission and 1 (7.1%) with partial remission. Although there was no marked difference in the overall remission rate, the complete remission rate was significantly higher in Group B than in Group A (p=0.02). Furthermore, there was a statistically significant difference between the groups in the time from the start of the study to complete remission (10.2±7.8 months in Group A; 9.5±6.1 months in Group B, p=0.03). Conclusion The combination of cyclosporine and low-dose corticosteroid treatment is an effective and important option in the management of patients with IMN with nephrotic-range proteinuria, either as an initial therapy or as a long-term treatment.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"2541-2548"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detection of Four Cases of Familial Hypercholesterolemia during a Workers' Compensation Insurance Secondary Health Examination. 工伤保险二次体检中家族性高胆固醇血症4例的检测。

IF 1.1 4区医学

Internal Medicine Pub Date : 2025-09-01 Epub Date: 2025-05-21 DOI: 10.2169/internalmedicine.4790-24

Takayuki Yamaji, Aya Mizobuchi, Yukihito Higashi

引用次数: 0